MEI Pharma and Infinity Pharmaceuticals Announce Definitive All-Stock Merger

Akers Biosciences and MyMD Pharmaceuticals Announce Definitive Merger Agreement

November 12, 2020

Pharmaceuticals

Akers Biosciences (NASDAQ: AKER) and MyMD Pharmaceuticals have entered into a definitive merger agreement that will combine the two companies into a single Nasdaq-listed company to be renamed MyMD Pharmaceuticals, Inc. The transaction, expected to close in H1 2021, gives current MyMD shareholders approximately 80% of the combined company and is intended to provide MyMD access to public capital and Akers' resources to accelerate development and commercialization of MyMD's immunotherapy pipeline.

Ipsen Acquires Epizyme to Expand Oncology Portfolio

August 12, 2022

Pharmaceuticals

Ipsen completed its acquisition of Epizyme under a definitive merger agreement, acquiring all outstanding shares for $1.45 per share plus a contingent value right (CVR) of $1.00 per share. The deal expands Ipsen’s oncology portfolio with Epizyme’s lead medicine Tazverik (tazemetostat) and development candidate EZM0414, among other preclinical programs.

Gemini Therapeutics and Disc Medicine Announce Definitive Merger Agreement

August 10, 2022

Healthcare Services

Gemini Therapeutics (Gemini) and Disc Medicine (Disc) entered into a definitive, all-stock merger agreement to combine the companies into a NASDAQ-listed, clinical-stage biopharmaceutical focused on advancing Disc’s hematology pipeline. The merged company is expected to have about $175 million in cash at closing, including $53.5 million from a concurrent financing led by Access Biotechnology and including OrbiMed and other healthcare investors, with the merger expected to close in Q4 2022.

GlycoMimetics to Acquire Crescent Biopharma (Merger to Operate as Crescent Biopharma, Inc.)

October 29, 2024

Healthcare Services

GlycoMimetics entered into an acquisition agreement with privately held oncology-focused biotechnology company Crescent Biopharma. The combined company will operate under the name Crescent Biopharma, Inc., advancing Crescent’s precision-engineered biologics for solid tumors, including the lead program CR-001, alongside ADC programs CR-002 and CR-003, supported by approximately $200 million in committed financing. GlycoMimetics stockholders approved the proposed merger in June 2025, and the combined company is expected to begin trading on Nasdaq on June 16, 2025 under the new ticker.

Sanofi to Acquire Blueprint Medicines to Expand Rare Immunology Pipeline

June 2, 2025

Pharmaceuticals

Sanofi and Blueprint Medicines entered into an agreement under which Sanofi will acquire Blueprint via a cash tender offer and subsequent merger. The deal values Blueprint at $129.00 per share in cash (approximately $9.1 billion equity value), with additional potential milestone payments tied to BLU-808 via a contingent value right.

Axcelis Technologies and Veeco Instruments to Combine in All-Stock Merger

October 1, 2025

IT Services

Axcelis Technologies and Veeco Instruments have entered into a definitive agreement to combine in an all-stock merger. The transaction is expected to close in the second half of 2026, subject to shareholder approvals, regulatory approvals, and customary closing conditions.